NASHUA, N.H. and ORLANDO, Fla., March 3, 2017 /PRNewswire/ -- (Booth #3413) – iCAD,
"We now have up to six years of positive clinical research supporting the use of the Xoft System as a safe and effective treatment for NMSC with many valuable benefits for patients including low recurrence rates and toxicity, added convenience, and excellent cosmesis," said Ken Ferry, CEO of iCAD. "In recent years, rates of NMSC have risen to epidemic levels, further underscoring the clinical need for a targeted, non-invasive, pain-free treatment option that allows physicians to provide quality care and patients to return to daily activities immediately."
Xoft skin eBx is an innovative option for certain patients who are not candidates for other forms of NMSC treatment, such as Mohs micrographic dermatologic surgery, surgical excision, curettage or cryosurgery. Its proprietary, miniaturized, low-energy x-ray source delivers a precise dose of targeted radiation directly to the lesion while reducing the risk of damage to surrounding healthy tissue. Appropriate candidates for Xoft skin eBx include NMSC patients with lesions in anatomically challenging locations (such as the ear, nose, scalp, neck, shin, and elbow), patients who may have challenges with wound healing, patients who are on anticoagulants, or those with medical comorbidities that may preclude them from surgery.
"The Xoft System is also convenient for physicians to use. The entire system can be easily wheeled from room to room within a medical facility," said Rakesh Patel, MD, Radiation Oncologist and Medical Director, Department of Radiation Oncology, Good Samaritan Hospital, Los Gatos, CA. "Additionally, radiation is delivered from an electronic source rather than a radionuclide-based source, which reduces the risk of radiation exposure for healthcare workers and eliminates the need to install a shielded vault, making it a cost-effective treatment modality for physicians who want to offer a range of clinical options to treat patients with NMSC."
iCAD will be hosting Lunch and Learn presentations by leading skin eBx physicians including Hayes B. Gladstone, MD, Gladstone Clinic, San Ramon, CA, Ilya Reyter, MD, American Skin Institute, Sherman Oaks, CA and Rakesh Patel, MD during the meeting in booth #3413 from 12-1 pm ET on Saturday, March 4th and Sunday, March 5th. For more information, or to register for an in-booth demonstration, visit go.icadmed.com/AAD2017.
"Mohs micrographic dermatologic surgery is considered the standard of care for NMSC, and for many patients, it can be a suitable treatment option," added Ferry. "But for patients who are not candidates for surgery, Xoft skin eBx represents an important advancement in patient care that can allow patients to maintain quality of life in the years ahead."
About Xoft Axxent Electronic Brachytherapy System
The Xoft System is an isotope-free radiation treatment that is FDA cleared, CE marked, and licensed in a growing number of countries for the treatment of cancer anywhere in the body, including treatment of early-stage breast cancer, gynecological cancers and non-melanoma skin cancer. It utilizes a proprietary miniaturized x-ray as the radiation source that delivers precise treatment directly to cancerous areas while sparing healthy tissue and organs. The Xoft System requires only minimal shielding and therefore does not require room redesign or construction investment. Minimal shielding also allows medical personnel to remain in the room with the patient during treatment. The mobility of the Xoft System makes it easy to treat patients at multiple locations and to easily store the system when not in use. The Axxent Hub is a cloud-based oncology collaboration software solution that enables centers to monitor treatment workflow and enhance communication between clinical specialists. Xoft is a wholly owned subsidiary of iCAD, Inc. For more information about Xoft visit www.xoftinc.com, like us on Facebook or follow us on Twitter at @xofticad.
About iCAD, Inc.
iCAD delivers innovative cancer detection and radiation therapy solutions and services that enable clinicians to find and treat cancers earlier and faster while improving patient outcomes. iCAD offers a comprehensive range of upgradeable computer aided detection (CAD) and workflow solutions to support rapid and accurate detection of breast, prostate and colorectal cancers. iCAD's Xoft® Axxent® Electronic Brachytherapy (eBx®) System® delivers high dose rate, low energy radiation, which targets cancer while minimizing exposure to surrounding healthy tissue. The Xoft System is FDA cleared and CE marked for use anywhere in the body, including treatment of non-melanoma skin cancer, early-stage breast cancer and gynecological cancers. The comprehensive iCAD technology platforms include advanced hardware and software as well as management services designed to support cancer detection and radiation therapy treatments. For more information, visit or www.icadmed.com or www.xoftinc.com.
"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995
Certain statements contained in this News Release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve a number of known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, but are not limited to the Company's ability to defend itself in litigation matters, to achieve business and strategic objectives, the risks of uncertainty of patent protection, the impact of supply and manufacturing constraints or difficulties, uncertainty of future sales levels, protection of patents and other proprietary rights, the impact of supply and manufacturing constraints or difficulties, product market acceptance, possible technological obsolescence of products, increased competition, litigation and/or government regulation, changes in Medicare or other reimbursement policies, risks relating to our existing and future debt obligations, competitive factors, the effects of a decline in the economy or markets served by the Company; and other risks detailed in the Company's filings with the Securities and Exchange Commission. The words "believe", "demonstrate", "intend", "expect", "estimate", "will", "continue", "anticipate", "likely", "seek", and similar expressions identify forward-looking statements. Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date the statement was made. The Company is under no obligation to provide any updates to any information contained in this release. For additional disclosure regarding these and other risks faced by iCAD, please see the disclosure contained in our public filings with the Securities and Exchange Commission, available on the Investors section of our website at http://www.icadmed.com and on the SEC's website at http://www.sec.gov.
For iCAD investor relations:
The Ruth GroupZack Kubow, 646-536-7030www.theruthgroup.com [email protected]
For iCAD media inquiries:
Berry & Company Public Relations, LLCLynn Granito, [email protected]
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/icad-showcases-targeted-non-surgical-non-melanoma-skin-cancer-treatment-at-aad-2017-300417540.html
SOURCE iCAD, Inc.
Subscribe to our Free Newsletters!
High blood pressure or hypertension is a chronic condition, which usually lasts a lifetime once it ...
This cancer affects men over the age of 50 years and screening with rectal examination and PSA can ...
Hyperacusis is a chronic hearing disorder characterized by an abnormal sensitivity to s ...View All